Key result
Observational studies suggest perioperative statins reduce mortality in non-cardiac surgery, but randomized trials fail to show consistent cardiovascular risk reduction in statin-naïve patients.
Why the study?
Meta-analyses of prospective observational studies have provided conflicting evidence on perioperative statin therapy in non-cardiac surgery, and data from randomized controlled trials remain scarce.
Does perioperative statin therapy reduce cardiovascular complications and mortality in patients undergoing non-cardiac surgery?
Does perioperative statin therapy reduce cardiovascular complications and mortality in patients undergoing non-cardiac surgery?
While continuing statin therapy is recommended for surgical patients with established atherosclerotic cardiovascular disease, current evidence does not support initiating statins in statin-naive patients prior to non-cardiac surgery.
May support perioperative statin use in non-cardiac surgery; leaves open definitive benefit pending randomized trials.
In this review, we discuss clinical evidence-based data regarding the potential benefit of statin therapy in the perioperative period of non-cardiac surgery. Results from meta-analyses of prospective observational studies have provided conflicting evidence. Moreover, comparison among studies is complicated by varying data sources, outcome definitions, types of surgery, and preoperative versus perioperative statin therapy. However, results of two recent large prospective cohort studies showed that statin use on the day of or the day after non-cardiac surgery (or both) is associated with lower 30-day all-cause mortality and reduction in a variety of postoperative complications, predominantly cardiac, compared with non-use during this period. There is a paucity of data from randomized controlled trials assessing the benefit of statin therapy in non-cardiac surgery. No randomized controlled trials have shown that initiating a statin in statin-naïve patients may reduce the risk of cardiovascular complications in non-cardiac surgeries. One randomized clinical trial demonstrated that the use of a preoperative statin in patients with stable coronary heart disease treated with long-term statin therapy had a significant reduction in the incidence of myocardial necrosis and major adverse cardiovascular events after non-cardiac surgery. In conclusion, it is important that all health-care professionals involved in the care of the surgical patient emphasize the need to resume statin therapy, particularly in patients with established atherosclerotic cardiovascular disease. However, initiating a statin in statin-naïve patients undergoing non-cardiac surgery needs more evidence-based data.
No takes yet. Share an insight, caveat, or question.
Mohebi et al. (2019) conducted a review in Non-cardiac surgery. Statins vs. No statin therapy / Placebo was evaluated. Observational studies suggest perioperative statins reduce mortality in non-cardiac surgery, but randomized trials fail to show consistent cardiovascular risk reduction in statin-naïve patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: